The effect of anti-CD44 monoclonal antibodies on differentiation and proliferation of human acute myeloid leukemia cells

Leukemia & Lymphoma
Z GadhoumF Smadja-Joffe

Abstract

Acute myeloid leukemia (AML) is a clonal malignant disease characterized by an increasing number of immature myeloid cells arrested at various stages of granulocytic and monocytic differentiation. The stage of the blockage defines distinct AML subtypes (AML1 to AML5 are the most frequent ones). There is increasing evidence that the malignant clone is maintained by rare AML stem cells endowed with self-renewal capacity, which through extensive proliferation coupled to partial differentiation, generate leukemic progenitors and blasts, of which the vast majority have limited proliferative capacity. Contrarily to chemotherapy alone, which is still unable to cure most AML patients, the differentiation therapy, which consists in releasing the differentiation blockage of leukemic blasts, has succeeded, when it is combined with chemotherapy, to greatly improve the survival of AML3 patients, using retinoic acid as differentiating agent. However, this molecule is ineffective in other AML subtypes, which are the most frequent. We have shown that specific monoclonal antibodies (mAbs, H90 and A3D8) directed to the CD44 cell surface antigen, that is strongly expressed on human AML blasts, are capable of triggering terminal differentiation of...Continue Reading

References

Jan 1, 1979·Acta Haematologica·T M Dexter
Dec 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·G R ScreatonJ I Bell
Nov 15, 1990·International Journal of Cancer. Journal International Du Cancer·S ReberM Zöller
Feb 1, 1990·The Journal of Experimental Medicine·K MiyakeP W Kincade
Jan 1, 1994·The Journal of Cell Biology·C R MackayU Günthert
Jan 1, 1995·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·P RuizU Günthert
Jan 1, 1994·Methods in Enzymology·I Stamenkovic, A Aruffo
Jul 1, 1993·Journal of Leukocyte Biology·F Lund-Johansen, L W Terstappen
Jul 1, 1993·The Journal of Cell Biology·R J PeachA Aruffo
Feb 1, 1993·The Journal of Experimental Medicine·S SeiterM Zöller
Feb 2, 1996·The Journal of Biological Chemistry·T E TaherS T Pals
May 29, 1996·International Journal of Cancer. Journal International Du Cancer·V TrochonH Lu
May 1, 1996·Leukemia & Lymphoma·F Smadja-JoffeJ P Levesque
Oct 23, 1997·Current Opinion in Cell Biology·P W KincadeL Hanson
Mar 20, 1998·International Journal of Cancer. Journal International Du Cancer·V ZawadzkiM Zöller
Sep 3, 1998·The Journal of Clinical Investigation·J MollP Herrlich
Jun 23, 1999·Experimental Hematology·S GhaffariC Eaves
Jul 9, 1999·Immunology Letters·Z Rozsnyay
Dec 28, 1999·Leukemia & Lymphoma·S IlangumaranD C Hoessli
Jan 5, 2000·Proceedings of the National Academy of Sciences of the United States of America·L WeissD Naor
Sep 7, 2000·The Journal of Cell Biology·L S ShermanN Ratner
Nov 4, 2000·Expert Opinion on Investigational Drugs·P Maslak, D Scheinberg

❮ Previous
Next ❯

Citations

Jul 9, 2013·Leukemia Research·Dayle A DainesRobert J McKallip
Apr 26, 2014·Immunotherapy·Cord Naujokat
Oct 28, 2008·Nature Chemical Biology·Samah Zeineb Gadhoum, Robert Sackstein
Apr 6, 2011·Expert Opinion on Biological Therapy·Roberto ScatenaBruno Giardina
Oct 11, 2015·Journal of Drug Targeting·George MattheolabakisMansoor M Amiji
Jul 24, 2012·Cancer Letters·Christoph LutzAnthony D Ho
Jun 29, 2010·Critical Reviews in Oncology/hematology·J Loeffler-RaggR Stauder
Apr 4, 2007·Leukemia Research·Jane L LiesveldCamille N Abboud
Feb 1, 2006·British Journal of Haematology·Ronald W StamRob Pieters
May 17, 2012·Biotechnology Journal·Van Thanh HoangAnthony D Ho
Sep 22, 2009·Journal of Cellular and Molecular Medicine·Mohini RajasagiRachid Marhaba
Mar 26, 2013·Oncoimmunology·Sylvia SnauwaertTessa Kerre
Oct 14, 2011·Leukemia Research·Arnaud SansonettiJacqueline Robert-Lézénès
Sep 30, 2016·Cellular Oncology (Dordrecht)·Antonieta Chavez-GonzalezSadegh Babashah
Sep 27, 2014·World Journal of Stem Cells·Jianbiao Zhou, Wee-Joo Chng
Nov 9, 2016·World Journal of Stem Cells·Maximilian StahlAmer M Zeidan
Jun 2, 2007·Journal of Cellular Physiology·Gang-Ming Zou
May 3, 2008·Journal of Cellular Biochemistry·Pei-Chun LiaoHsuan-Kuang Jung
Aug 26, 2017·Cancer Immunology, Immunotherapy : CII·Smarakan SnehaTrivadi Sundaram Ganesan
Oct 24, 2020·Drug Delivery and Translational Research·Jin CaoJayanth Panyam
May 8, 2021·European Journal of Pharmacology·Zohreh YaghobiBehzad Baradaran

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adult Stem Cells

Adult stem cells reside in unique niches that provide vital cues for their survival, self-renewal, and differentiation. They hold great promise for use in tissue repair and regeneration as a novel therapeutic strategies. Here is the latest research.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.